Literature DB >> 27405938

[Clinical course and differential diagnosis of thrombotic microangiopathy].

M Guthoff1, N Heyne2.   

Abstract

BACKGROUND: Thrombotic microangiopathies are complex diseases, requiring early differential diagnosis and targeted intervention.
OBJECTIVES: Presentation of clinical phenotype and diagnostic algorithm, discussion of underlying pathophysiology, clinical management and therapy.
METHODS: Summary of current knowledge from literature and expert opinion.
RESULTS: Our understanding of pathophysiology and therapeutic options have changed substantially in recent years. Early differential diagnosis and targeted therapy are of prognostic relevance.
CONCLUSIONS: A better understanding of underlying pathophysiology, increased clinical awareness and novel therapeutic options allow for a better prognosis of patients with thrombotic microangiopathy.

Entities:  

Keywords:  STEC-HUS; TTP; Thrombotic microangiopathy; aHUS

Mesh:

Year:  2016        PMID: 27405938     DOI: 10.1007/s00063-016-0193-5

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN: 2193-6218            Impact factor:   0.840


  26 in total

1.  [Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia].

Authors:  C GASSER; E GAUTIER; A STECK; R E SIEBENMANN; R OECHSLIN
Journal:  Schweiz Med Wochenschr       Date:  1955-09-20

Review 2.  How I treat refractory thrombotic thrombocytopenic purpura.

Authors:  Farzana A Sayani; Charles S Abrams
Journal:  Blood       Date:  2015-03-17       Impact factor: 22.113

3.  Platelet count and prothrombin time help distinguish thrombotic thrombocytopenic purpura-hemolytic uremic syndrome from disseminated intravascular coagulation in adults.

Authors:  Yara A Park; Michael R Waldrum; Marisa B Marques
Journal:  Am J Clin Pathol       Date:  2010-03       Impact factor: 2.493

4.  Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

Authors:  C M Legendre; C Licht; P Muus; L A Greenbaum; S Babu; C Bedrosian; C Bingham; D J Cohen; Y Delmas; K Douglas; F Eitner; T Feldkamp; D Fouque; R R Furman; O Gaber; M Herthelius; M Hourmant; D Karpman; Y Lebranchu; C Mariat; J Menne; B Moulin; J Nürnberger; M Ogawa; G Remuzzi; T Richard; R Sberro-Soussan; B Severino; N S Sheerin; A Trivelli; L B Zimmerhackl; T Goodship; C Loirat
Journal:  N Engl J Med       Date:  2013-06-06       Impact factor: 91.245

Review 5.  Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches.

Authors:  Magdalena Riedl; Fadi Fakhouri; Moglie Le Quintrec; Damien G Noone; Therese C Jungraithmayr; Veronique Fremeaux-Bacchi; Christoph Licht
Journal:  Semin Thromb Hemost       Date:  2014-06-09       Impact factor: 4.180

6.  An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.

Authors:  Josep M Campistol; Manuel Arias; Gema Ariceta; Miguel Blasco; Mario Espinosa; Josep M Grinyó; Manuel Praga; Roser Torra; Ramón Vilalta; Santiago Rodríguez de Córdoba
Journal:  Nefrologia       Date:  2013-01-18       Impact factor: 2.033

7.  [Treatment of typical hemolytic-uremic syndrome. Knowledge gained from analyses of the 2011 E. coli outbreak].

Authors:  J Menne; J T Kielstein; U Wenzel; R A K Stahl
Journal:  Internist (Berl)       Date:  2012-12       Impact factor: 0.743

8.  Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study.

Authors:  Jan Menne; Martin Nitschke; Robert Stingele; Mariam Abu-Tair; Jan Beneke; Jörn Bramstedt; Jan P Bremer; Reinhard Brunkhorst; Veit Busch; Reinhard Dengler; Günther Deuschl; Klaus Fellermann; Helmut Fickenscher; Christoph Gerigk; Alexander Goettsche; Jobst Greeve; Carsten Hafer; Friedrich Hagenmüller; Hermann Haller; Stefan Herget-Rosenthal; Bernd Hertenstein; Christina Hofmann; Melanie Lang; Jan T Kielstein; Ulrich C Klostermeier; Johannes Knobloch; Markus Kuehbacher; Ulrich Kunzendorf; Hendrik Lehnert; Michael P Manns; Tobias F Menne; Tobias N Meyer; Claus Michael; Thomas Münte; Christine Neumann-Grutzeck; Jens Nuernberger; Hermann Pavenstaedt; Leyla Ramazan; Lutz Renders; Jonas Repenthin; Wolfgang Ries; Axel Rohr; Lars Christian Rump; Ola Samuelsson; Friedhelm Sayk; Bernhard M W Schmidt; Sabine Schnatter; Harald Schöcklmann; Stefan Schreiber; Cay U von Seydewitz; Jürgen Steinhoff; Sylvia Stracke; Sebastian Suerbaum; Andreas van de Loo; Martin Vischedyk; Karin Weissenborn; Peter Wellhöner; Monika Wiesner; Sebastian Zeissig; Jürgen Büning; Mario Schiffer; Tanja Kuehbacher
Journal:  BMJ       Date:  2012-07-19

Review 9.  Bench-to-bedside review: thrombocytopenia-associated multiple organ failure--a newly appreciated syndrome in the critically ill.

Authors:  Trung C Nguyen; Joseph A Carcillo
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

10.  Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies.

Authors:  Christoph Licht; Larry A Greenbaum; Petra Muus; Sunil Babu; Camille L Bedrosian; David J Cohen; Yahsou Delmas; Kenneth Douglas; Richard R Furman; Osama A Gaber; Timothy Goodship; Maria Herthelius; Maryvonne Hourmant; Christophe M Legendre; Giuseppe Remuzzi; Neil Sheerin; Antonella Trivelli; Chantal Loirat
Journal:  Kidney Int       Date:  2015-02-04       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.